Arrowhead Pharmaceuticals, based in Pasadena, California, develops RNA-based therapies targeting intractable diseases, employing 525 staff and featuring 14 clinical-stage investigational medicines across various therapeutic areas. Their TRiMTM platform enables tissue-specific delivery through RNA interference mechanisms.
Patrick O'Brien sold 29,184 shares of ARWR on 6 January at $20.10 per share, worth a total of $587K. They now own 544,727 ARWR shares, or a 5% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
